Life Science specialty chemical company BioNeutral Group Inc (OTCBB: BONU) said it received final test results from ATS Labs indicating that its Ygiene hospital grade antimicrobial has passed the stringent Sporicidal GLP test requirements for hospital and medical environment sporicide efficacy claims mandated by the US Environmental Protection Agency (EPA).
GLP stands for good laboratory practice which, in the clinical and research arena, generally refers to a system of management controls for laboratories and research organizations to ensure the consistency and reliability of results.
Bio Neutral said today this key test demonstrates that Ygiene hospital grade antimicrobial completely eliminates harmful spores. With the completion of this officially required GLP testing, BioNeutral is now positioned to apply for approval of its Ygiene hospital grade antimicrobial as a bactericide, fungicide and sporicide with the US EPA.
It plans to proceed with these registrations in consultation with its advisors in order to move forward with the commercialization of its Ygiene hospital grade antimicrobial.
Dr. Andy Kielbania, Chief Scientist at BioNeutral, stated: “We believe that these new test results show we have a superior sporicide compared to currently available products. With our approvals in the major European countries along with our previous results demonstrating sporicidal efficacy required for Canadian and Australian registration, we are now in a position to move forward in many of the major markets of the world.”
Currently, BioNeutral is focused on two kinds of products: bioneutralisers (Ygiene) and chemoneutralisers (Ogiene).The Ogiene product platform is designed to neutralize toxic and noxious gases and liquids, as well as dissolve and/or break down substances that stain surfaces and fabrics. BioNeutral states that Ogiene is water-based and environmentally friendly, furthermore it leaves no harmful residue.
Unlike Ygiene - BioNeutral’s other product family - Ogiene is not designed as an anti-microbial compound, therefore it is not subject to regulatory approval prior to sale. The Ogiene product family consists of a variety of multi-purpose cleaners, odor removers and paint removers.
Bioneutral’s bioneutraliser product family, based on the proprietary Ygiene formulation, act as disinfectants, decontaminates and sterilizers. These antimicrobials are designed to address the unmet needs of consumers and hospitals, and they also have industrial, security and military applications.
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
No comments:
Post a Comment